Vosoritide (Voxzogo®)

Assessment Status Full HTA submission received from Applicant
HTA ID 22028
Drug Vosoritide
Brand Voxzogo®
Indication For the treatment of genetically confirmed achondroplasia in patients aged two years and older whose epiphyses are not closed.
Assessment Process
Rapid review commissioned 09/05/2022
Rapid review completed 01/06/2022
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of vosoritide compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 01/07/2022
Pre-submission consultation with Applicant 26/09/2022
Full submission received from Applicant 21/03/2023